Novartis data underscore pioneering scientific innovation in Hematology and Oncology at ASH and SABCS

Core Insights - Novartis will present over 70 abstracts at the upcoming ASH and SABCS meetings, highlighting advancements in hematology and oncology, including 11 oral presentations and a late-breaker abstract for the Phase III VAYHIT2 trial of ianalumab in immune thrombocytopenia (ITP) [1][2][3] Hematology Highlights - The pivotal Phase III trial results for ianalumab in ITP patients previously treated with corticosteroids will be presented as a late-breaker [3] - Scemblix (asciminib) shows continued improvement in patient-reported outcomes compared to investigator-selected tyrosine kinase inhibitors in newly diagnosed chronic myeloid leukemia (CML) [2][3] - The 96-week data from the Phase III MANIFEST-2 study of pelabresib plus ruxolitinib in myelofibrosis represents the longest follow-up in a randomized combination trial [3] Oncology Highlights - Kisqali (ribociclib) data from the MONALEESA studies indicate long-term benefits for early and metastatic breast cancer patients [3] - The pooled analysis of patients treated with first-line ribociclib plus endocrine therapy shows long-term progression-free survival [5] - Five-year analysis of distant disease-free survival from the NATALEE trial of ribociclib plus a nonsteroidal aromatase inhibitor in HR+/HER2− early breast cancer patients will be presented [5] Product Information - Novartis has a strong legacy in hematology, having delivered over 10 medicines for more than 15 blood cancers and serious blood disorders over the past two decades [7][8] - The company has been at the forefront of scientific advancements in breast cancer for over 30 years, leading in the discovery of new therapies and combinations [9]